Slide 1: Report FY 2025 Faes Farma
REPORT FY 2025 Faes Farma
Slide 2: Index
INDEX 1/ Highlights and key figures 2/ Business evolution 2025 3/ 2025 results and 2026 guidance
Slide 3: Highlights and key figures
1/ Highlights and key figures
Slide 4: Highlights 2025
HIGHLIGHTS AND KEY FIGURES 2025 Highlights 2025 Business / Total revenues +23% (+11% excluding M&A), in the high guidance range, driven by growth in all business areas. / Pharma revenues +21%, with the LATAM market (+20%) and Licenses (+9%) being the main growth drivers. / Adjusted EBITDA +3,1% excl
Slide 5: Key figures 2025, in line with guidance
HIGHLIGHTS AND KEY FIGURES 2025 Key figures 2025 , in line with guidance REVENUES 2025 vs GUIDANCE Reported revenues Revenue ex. M&A Net debt/adjusted Ebitda 627.0 M€ 563.7 M€ 267 M€ +11% +8%/10% x2 x2 +23% guidance Ebitda aj. orgánico EBITDA Reported EBITDA EBITDA ex. M&A Adjusted EBITDA * 118.0
Slide 6: Business evolution 2025
2/ Business evolution 2025
Slide 7: Balanced growth across all areas of the Group
BUSINESS EVOLUTION 2025 Balanced growth across all areas of the Group Revenues by porfolio line Revenues by portfolio line (€M) 2025 2024 % 13% Animal nutrition and health Pharma 551.7 456.6 21% 35% Pharma top 3 molecules 219.3 198.3 11% Top 3 molecules Rest of Pharma 332.4 258.5 29% Animal Nutritio
Slide 8: Highlights of the main molecules
BUSINESS EVOLUTION 2025 Highlights of the main molecules Very positive evolution with excellent performance in both direct sales and Licenses Bilastine Strong performance throughout the year, with growth of +8% driven by positive performance in both 134.2 M€ licensing and direct sales, particularly
Slide 9: All business areas trending positive
BUSINESS EVOLUTION 2025 All business areas trending positive Revenues by business area (€M) Revenues by business area 2025 2024 % 13% Animal nutrition and health Pharma 551.7 456.6 21% Pharma Iberia 230.8 207.5 11% 37% Pharma Iberia Pharma International (without licenses) 207.7 145.6 43% Pharma Lice
Slide 10: Pharma Iberia, sustained growth in prescription and the incorporation of Laboratorio Edol
BUSINESS EVOLUTION 2025 Pharma Pharma Iberia, sustained growth in prescription and the incorporation of Laboratorio Edol Iberia revenues: 230.8 M€ +11% Revenues of Pharma Iberia in €M /01 Spain SPAIN +0,1% Prescription grew slightly +2% with positive evolution especially in 173.9 +0,1% 174.1 bilasti
Slide 11: Pharma International, Latam as the growth engine
BUSINESS EVOLUTION 2025 Pharma Pharma International, Latam as the growth engine International revenues: 207.7 M€, +43% Revenues of Pharma International in €M /01 LATAM +20% LATAM +20% 117.1 Latin America is the company's main area of organic growth. Chile +12%, 97.5 Colombia +19%, Ecuador +34%, Peru
Slide 12: Licences, good performance across all molecules
BUSINESS EVOLUTION 2025 Pharma Licences, good performance across all molecules Licences revenues: 113.2 M€ +9% Licences revenues in €M /01 BILASTINE +3% Bilastine Bilastine continues to grow, driven mainly by Asia Pacific, with 84 +3% 86.3 good overall performance in both mature markets and expandin
Slide 13: Animal nutrition and health
BUSINESS EVOLUTION 2025 Farm Animal nutrition and health FARM Faes revenues in €M FARM Faes revenues: 79.6 M€ +52% /01 Significant growth in revenue, with the ISF business as the main driver, with revenue continuing to exceed expectations. Margins are under pressure from the product +52% 79.6 mix. 5
Slide 14: Sustainability
Sustainability “Focused on a sustainable F uture”, new 2025-2030 sustainability strategy aligned with the global strategy PEOPLE PATIENTS ENVIRONMENTAL CONDUCT PARTNERSHIP 55% women in the workforce. Role of ‘Patient Relations Plan for Climate Change Board of Directors: Update of the 'Third Speciali
Slide 15: Results and outlook
af FAES FARMA Results and outlook emia
Slide 16: Clear financial priorities
Clear financial priorities Financial integration of Sifi y Edol. Business profitability. Cash flow management. Discipline in capital allocation. Solid balance sheet and strengthened liquidity.
Slide 17: P&L Highlights 2025
RESULTS AND OUTLOOK P&L Results Thousand € 2025 2024 %change Highlights 2025 Ordinary income (sales) 610,464 493,647 23,7% Other operating income 16,524 16,394 0,8% /01 – Income Tota Income 626,988 510,041 22,9% • Double-digit growth exceeding guidance, driven by International Cost of sales -214,550
Slide 18: Free cash Flow. Resilience in a year of inorganic growth
RESULTS AND OUTLOOK Free cash Flow. Resilience in a year of inorganic growth /01 –Working capital Increase resulting from the rise in stocks related to the transfer Free Cash Flow process to the new plant in Derio and the integration of Sifi and Edol. miles € 2025 /02 – Capex Total net income 626,98
Slide 19: Capital allocation aligned with our Strategic Plan
Capital allocation aligned with our Strategic Plan Execution of two inorganic growth operations in 2025 to support and accelerate the Group’s growth and expand both its product portfolio and international presence. Throughout 2026, the move to the new Derio plant will be completed, thus culminating
Slide 20: Solid balance sheet, strengthened liquidity and comfortable maturity profile
Solid balance sheet, strengthened liquidity and comfortable maturity profile Net debt evolution (€ M) 55,6 267,3 344,2 Net debt/adjusted EBITDA ≈ 2x -66,8 2,5 13 -81,2 ND DN2024 2024 FCO FCO Financials Financieros Taxes Impuestos Acquisitions Adquisiciones Dividend Dividendo ND 2025 DN 2025 Debt mat
Slide 21: 2026 Guidance and main drivers
2026 Guidance and main drivers REVENUES 2026 EBITDA 2026* LEVERAGE 2026 +17% / +19% +28% / +31 % < 2x Ebitda Vs. 627 M€, 2025 vs 118 M€, 2025 Main growth drivers 2026 ∕ Growth in the strategic international areas of LATAM and Gulf offsetting the impact of the LOE of the bilastine license in Japan. ∕
Slide 22: Q&A
af FAES FARMA ofp ens FAT Q&A
Slide 23: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an of
Slide 24: Appendix
Appendix REVENUES PHARMA IBERIA REVENUES INTERNACIONAL (without licensing) REVENUES LICENSING REVENUES FARM FAES 2025 2024* %var 2025 2024* %var 2025 2024* %var 2025 2024* %var Pharma Spain 174.1 173.9 0% International 207.7 145.6 43% Licensing 113.2 103.7 9% Animal health and nutrition 79.6 52.3 52